LARGE SCALE AUTOMATED DNA SEQUENCING OF HUMAN GENES

此次收购的目的是为了加快正在进行的遗传 研究，以获得诊断，治疗和 预防遗传性神经系统疾病。承包商将 在最密集的劳动力、空间和时间上进行基因研究 消费准备水平。 承包商应尽最大努力， 可重复的快速DNA模板生产和纯化 提供足够纯度的DNA用于高度准确的 自动化DNA序列分析和显著改进的技术 目前用于基因分型和定位克隆。据估计 承包商将被要求提供大约5000 纯化的DNA模板制备物/年 目的克隆中的缺失;以 每200个DNA样本/年约300个标记;执行 筛选约10个文库。DNA的来源将是 由NINDS提供给承包商。NINDS DNA设施将 负责对所产生的材料和结果进行评价 由承包商负责。

The objectives of this acquisition are to speed up ongoing genetic research to obtain data critical for diagnosis, treatment and prevention of hereditary neurologic disorders. The Contractor will perform genetic research at the most labor intensive, space and time consuming preparatory level. The Contractor shall exert its best efforts to develop highly reproducible rapid DNA template production and purification procedures which provide DNA of sufficient purity for highly accurate automated DNA sequence analysis and significantly improve techniques currently used for genotyping and positional cloning. It is estimated that the Contractor will be required to provide approximately 5,000 purified DNA template preparations/year by generating nested deletions in clones of interest; perform genotyping in the amount of approximately 300 markers per 200 DNA samples/year; perform screening of approximately 10 libraries. The sources of DNA will be provided to the Contractor by the NINDS. The NINDS DNA Facility will be responsible for evaluation of the materials and results produced by the Contractor.